Home / Blog
Global Igy Polyclonal Antibodies Revenue Is About 4.32 Million Usd In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
In the last several years, global market of IGY Polyclonal Antibodies developed rapidly, with an average growth rate of 14.05%. In 2017, global revenue of IGY Polyclonal Antibodies is about 4.32 million USD.

The classification of IGY Polyclonal Antibodies includes Primary Antibody and Secondary Antibody. The proportion of Primary Antibody in 2017 is about 70%, and the proportion of Secondary Antibody in 2017 is about 30%. 

IGY Polyclonal Antibodies are application in Academic Research and Commercial. The most of IGY Polyclonal Antibodies is used in Commercial, and the market share of that is about 60 % in 2017.

North America is the largest consumption place, with a consumption market share nearly 37.5% in 2017; Europe is the second largest consumption place with the consumption market share of 30% in 2017. 

Market competition is not intense. Merck, IGY Life Sciences, Abcam, Genway Biotech, Good Biotech etc. are the leaders of the industry with the market share are about 66% in 2017.